MedPath

A clinical trial to establish the proper diagnosis and therapy of Hypereosinophilic syndrome.

Not Applicable
Conditions
Hypereosinophilic syndrome, chronic eosinophilic leukemia
Registration Number
JPRN-UMIN000008653
Lead Sponsor
Kobe University Medical School Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1) Presence of any other active neoplasm 2) Prior anti-leukemic treatment within two weeks. 3) Psychological disorder 4) Hypersensitivity to ingredient of Imatinib 5) Pregnant or nursing women 3) Whom the investigator considered inappropriate to this study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Imatinib responsiveness; complete remission(CR) ratio, time to achievement, time to progression.
Secondary Outcome Measures
NameTimeMethod
1)Organic dysfunction caused by hepereosinophilia 2)Expression levels and stractual changes of F-P fusion mRNA, and mutational analysis in imatinib resistance 3)Adverse effects of Imatinib
© Copyright 2025. All Rights Reserved by MedPath